Pharmacological treatment of airway remodeling: Inhaled corticosteroids or antileukotrienes?

Annals of Clinical and Laboratory Science

Volumn 34, Issue 2, 2004, Pages 138-142

  Riccioni, Graziano ^a,b   Di Ilio, Carmine ^a   D'Orazio, Nicolantonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NONE   (Italy)

Author keywords

Airway inflammation; Antileukotrienes; Asthma; Bronchial hyper responsiveness; Budesonide; Cytokines; Inhaled corticosteroids; Montelukast; Remodeling; Zafirlukast

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; FLUTICASONE; KETOTIFEN; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL SODIUM; ZAFIRLUKAST; ZILEUTON;

AIRWAY REMODELING; ASTHMA; BASOPHIL; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; EOSINOPHIL; FOLLOW UP; HUMAN; INFLAMMATION; LAMINA PROPRIA; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; MUCUS SECRETION; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT DISEASE; REVIEW; SUBMUCOSA; TH2 CELL; AIRWAY OBSTRUCTION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

BRONCHUS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AIRWAY OBSTRUCTION; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 2542443714     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. National Asthma Education and Prevention Program. 1997. Expert Panel Report II: Guidelines for the diagnosis and management of asthma. National Heart, Lung, Blood Institute; Bethesda, ii-viii;1-50.
2. Holgate ST. The role of mast cells and basophils in inflammation. Clin Exp Allergy 2000;1:28-32.
3. Riccioni G, D'Orazio N, Della Vecchia R, Di Ilio C. Remodeling and inflammation in bronchial asthma. Eur J Infl 2003;1:9-12.
4. Weiss ST, Van Natta ML, Geiger RS. Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. Am J Respir Crit Care Med 2000;162:50-56.
5. Vignola AM, Kips J, Bousquet J. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol 2000;105:1041-1053.
6. Grol MH, Gerritsen J, Vonk JM, Shouten JP, Goeter JH, Rijcken B, Postma DS. Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 3-year follow-up study. Am J Respir Crit Care Med 1999;160:1830-1837.
7. Warner JO, Pohunek P, Marguet C, Clogh JB, Roche WR. Progression from allergic sensitization to asthma. Pediatr Allergy Immunol 2000;13:12-14.
8. Bousquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, Michel FB. Asthma: a disease remodeling the airways. Allergy 1992;47:3-11.
9. Tiddens H, Silverman M, Bush A. The role of inflammation in airway disease: remodeling. Am J Respir Crit Care Med 2000;162:S7-S10.
10. Kips JC, Pauwels RA. Airway wall remodeling: does it occur and what does it mean. Clin Exp Allergy 1999;29: 1457-1466.
11. Busquet J, Jeffrey PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-1745.
12. Moller GM, Overbeek SE, Van Helden-Meeuwsen CG, Van Haarst JM, Prens EP, Mulder PG, Postma DS, Hoogsteden HC. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: down-regulation by inhaled corticosteroids. Clin Exp Allergy 1996;26:517-524.
13. Polito AJ, Proud D. Epithelia cells as regulators of airway inflammtion. J Allergy Clin Immunol 1998;102:714-718.
14. Roche WR. Inflammatory and structural changes in the small airways in bronchial asthma. Am J Respir Crit Care Med 1998;157:S191-194.
15. US Department of Health and Human Services. National Heart, Lung and Blood Institute/World Health Organisation Workshop Report. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. National Heart, Lung, Blood Institute, Bethesda, 1995 (NIH Publication 95-3659).
16. Highlights of the Expert Panel Report II. Clinical practice guidelines for the diagnosis and management of asthma. National Heart, Lung, Blood Institute, Bethesda, 1997 (NIH publication 97-4051).
17. Horowitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998;157:1363-1371.
18. Barnes NC. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000;161:S73-S76.
19. Riccioni G, Santilli F, D'Orazio N, Sensi S, Spoltore R, De Benedictis M, Guagnano MT, Di Ilio C, Della Vecchia R. The role of antileukotrienes in the treatment of asthma. Int J Immunopathol Pharmacol 2002;15:171-182.
20. Ducharme F. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;326: 621-626.
21. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998;157:S1-S53.
22. Laitinen LA, Laitinen A. Remodeling of asthmatic airways by glucocorticoids. J Allergy Clin Immunol 1996;97:153-158.
23. The Childhood Asthma Management Program Research Group. Long-term effect of budesonide or nedocromil in children with asthma. NEJM 2000;343:1054-1059.
24. Boulet LP, Turcotte H, Laviolette M, Neud F, Bernier MC, Martel S, Chakir J. Airway responsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:1308-1313.
25. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995;152:45-52.
26. O'Byrne PM, Pedersen S. Measuring efficacy and safety of different inhaled corticosteroid preparations. J Allergy Clin Immunol 1998;102:879-886.
27. Phillips GH. Structure-activity relationship of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84:19-23.
28. Trigg CJ, Manolitsas ND, Wang J, Calderon MA, McAulay A, Jordan SE, Herdman MJ, Jhalli N, Duddle JM, Hamilton SA. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994;150:17-22.
29. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999;54:289-295.
30. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997;156:229-233.
31. Jeffrey PK, Godfrey RW, Adelroth E. Effect of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992;145:890-899.
32. Hogg JC. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999;54:283.
33. Sont JK, Willems LN, Bel H, van Krieken JH, Vanderbroucke JP, Sterk PJ. Clincal control and histopathologic outcome of asthma when using airway hyper-responsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-1047.
34. Barnes PJ. Current therapies for asthma. Promise and limitations. Chest 1997;3:17-26.
35. Djukanovic R, Lai CK, Wilson JW. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1999;256:669-672.
36. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effect of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Resp Dis 1993;147:1472-1478.
37. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-958.
38. Hood PP, Cotter TP, Costello JF, Sampson AP. Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax 1999;54:1075-1082.
39. Riccioni G, D'Orazio N, Di Ilio C, Della Vecchia R, De Lorenzo A. Effectiveness and safety of montelukast versus budesonide at different doses on bronchial reactivity in subjects with mild-persistent asthma. Clinica Terapeutica 2002;153:317-321.
40. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-1220.
41. Clark N, Jones P, Keller S, Vermeire P. Patient factor and compliance with asthma therapy. Pediatr Pulmonol 2000; 29:46-61.
42. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Heargrave FE. Effect of long term treatment with inhaled corticosteroids (budesonide) on airway hyperresponsiveness and clinical asthma in non-steroid dependent asthma. Am Rev Respir Dis 1990;142:832-836.
43. Volovitz B, Duenas-Meza F, Pinacho-Daza C, Kosa L, Leff JA. Results of a 6-month open extension study comparing montelukast to beclomthasone in children with asthma. Am J Respir Crit Care Med 2000;161:A37.
44. Firriolo KM, Edelman JM, Bratton D, Santanello N, Bird SR. Parent and child satisfaction for montelukast, aleukotriene receptor antagonist, compared with beclomethasone in asthmatic children with asthma. J Allergy Clin Immunol 2000;105:71-76.
45. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hucthinson AW, Gauthier JY, Lord A, Masson P, McAuliffe M, McFarlane CS, Metters KM, Pickjett C, Piechuta H, Rodger IW, Sawywe N, Young RN, Zamboni R, Abraham WM. Pharmacology of montelukast sodium (Singulair), a potent selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
46. Dempsey OJ, Wilson AM, Sims EJ, Mistry C, Lipworth BJ. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000;117:950-953.
47. Riccioni G, D'Orazio N, Della Vecchia R, Sensi S, Guagnano MT. Comparison of montelukast on bronchial reactivity in subjects with mild-moderate asthma. Pulm Pharmacol Ther 2003;16:111-114.
48. Riccioni G, Ballone E, Sensi E, Di Nicola M, Di Mascio R, Santilli F, Guagnano MT, Della Vecchia R. Effectiveness of monteukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopathol Pharmacol 2002;15:149-155.
49. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddcombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000;105:193-204.
50. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, Seidenberg BC, Capizzi T, Kundu S, Godard P. Randomised, placebo-controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319:87-90.